- Home
- FFA vs MREO Comparison
FFA vs MREO Comparison
Compare FFA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- MREO
- Stock Information
- Founded
- FFA 2004
- MREO 2015
- Country
- FFA United States
- MREO United Kingdom
- Employees
- FFA N/A
- MREO N/A
- Industry
- FFA Investment Managers
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- MREO Health Care
- Exchange
- FFA Nasdaq
- MREO Nasdaq
- Market Cap
- FFA 400.0M
- MREO 482.5M
- IPO Year
- FFA N/A
- MREO N/A
- Fundamental
- Price
- FFA $19.17
- MREO $2.50
- Analyst Decision
- FFA
- MREO Strong Buy
- Analyst Count
- FFA 0
- MREO 6
- Target Price
- FFA N/A
- MREO $7.83
- AVG Volume (30 Days)
- FFA 26.1K
- MREO 1.5M
- Earning Date
- FFA 01-01-0001
- MREO 03-26-2025
- Dividend Yield
- FFA 6.72%
- MREO N/A
- EPS Growth
- FFA N/A
- MREO N/A
- EPS
- FFA N/A
- MREO N/A
- Revenue
- FFA N/A
- MREO $1,000,000.00
- Revenue This Year
- FFA N/A
- MREO N/A
- Revenue Next Year
- FFA N/A
- MREO N/A
- P/E Ratio
- FFA N/A
- MREO N/A
- Revenue Growth
- FFA N/A
- MREO N/A
- 52 Week Low
- FFA $15.84
- MREO $2.25
- 52 Week High
- FFA $19.30
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- FFA 27.10
- MREO 38.26
- Support Level
- FFA $19.22
- MREO $2.39
- Resistance Level
- FFA $19.54
- MREO $2.59
- Average True Range (ATR)
- FFA 0.30
- MREO 0.17
- MACD
- FFA -0.13
- MREO 0.02
- Stochastic Oscillator
- FFA 3.17
- MREO 39.87
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).